Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients
Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective study showed. Brentuximab plus the alkylating agent dacarbazine (DTIC) produced an objective response rate (ORR) of 95% in 22 patients, whereas brentuximab plus nivolumab (Opdivo) […]
Clinical Challenges: Test Your Knowledge on Recent Advances in DLBCL
Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow. This three-question quiz will test one aspect from each article in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory […]
Opinion | Charting the Course: From Young Adult Leukemia Patient to Oncologist
Rosenthal is a lymphoma specialist. “Would you like to have a bone marrow biopsy today or tomorrow?” These are the only words I remember coming from the oncologist who I had just met in the emergency department (ED). I was in my second year of medical school and just 24 years old when I was […]
FDA Panel: Tolerating Approval Outliers Would Set ‘Dangerous Precedent’
An unprecedented wait for final FDA approval will drag on for two orphan lymphoma drugs, at least a little while longer, as the agency decides how to end the delays and prevent them from happening again. The dihydrofolate reductase inhibitor pralatrexate (Folotyn) received accelerated approval in 2009 and the histone deacetylase (HDAC) inhibitor belinostat (Beleodaq) […]
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis
Patients with diffuse large B-cell lymphoma (DLBCL) who also had pre-existing depression, anxiety, or both had a worse prognosis than those without these pre-existing mental health conditions, according to results from a population-based study. Among over 13,000 patients at a median follow-up of 2 years, the 5-year overall survival (OS) rate was 27% for patients […]
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma
In relapsed or refractory follicular lymphoma, treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) was associated with better outcomes compared with currently available therapies, a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials suggested. Overall response rate (ORR) was higher, and both progression-free survival (PFS) and overall survival (OS) were […]